睿昂基因收盘下跌2.14%，最新市净率1.24，总市值11.51亿元

Company Overview - Ruiang Gene's closing price on April 16 was 20.61 yuan, down 2.14%, with a latest price-to-book ratio of 1.24 and a total market capitalization of 1.151 billion yuan [1] - As of September 30, 2024, Ruiang Gene had 4,658 shareholders, an increase of 641 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] Business Operations - The main business of Shanghai Ruiang Gene Technology Co., Ltd. includes the research, production, sales, and scientific services of in vitro diagnostic products, with a focus on molecular diagnostic reagents [1] - The company's flagship product, the Bai Ruida leukemia testing kit, is the most comprehensive in terms of fusion gene types approved for sale in China, allowing the company to maintain a leading position in the domestic leukemia molecular diagnostics market [1] - Ruiang Gene has received several honors, including "Shanghai Specialized and Innovative Enterprise" and "Fengxian District Technology Small Giant Enterprise," and has undertaken multiple major scientific research projects led by various government departments [1] Financial Performance - In the latest quarterly report for Q3 2024, the company achieved operating revenue of 190 million yuan, a year-on-year decrease of 4.62%, and a net profit of 5.7273 million yuan, down 69.58% year-on-year, with a gross profit margin of 76.08% [1] Industry Comparison - Ruiang Gene's price-to-earnings ratio (TTM) is -79.59, with a price-to-earnings ratio (static) also at -79.59, and a price-to-book ratio of 1.24, compared to the industry average P/E ratio of 45.94 and a P/B ratio of 4.71 [2] - The industry median P/E ratio is 29.64, with a median P/B ratio of 2.35, indicating that Ruiang Gene is significantly below industry averages in terms of profitability metrics [2]